Exagen Inc. Reports Q1 2026 Earnings Beat with $17.31M Revenue
Exagen Inc. (XGN) held its First Quarter 2026 earnings conference call on May 11, 2026, to discuss financial results for the period ended March 31, 2026. The company reported a revenue of $17.31 million, representing an 11.67% year-over-year increase and beating analyst estimates by $897,430. Additionally, Exagen posted an earnings per share (EPS) of -$0.20, which surpassed expectations by $0.05. Key executives, including CEO John Aballi and CFO Jeffrey Black, participated in the call alongside Vice President of Investor Relations Tina Jacobsen. They addressed questions from analysts representing major financial institutions such as Canaccord Genuity, Craig-Hallum Capital Group, TD Cowen, BTIG, and KeyBanc Capital Markets. The discussion likely covered operational performance, strategic initiatives, and future outlooks, although specific dialogue details were not provided in the transcript header. The event underscores Exagen's continued financial trajectory in the diagnostic testing sector, highlighting its ability to exceed market expectations despite reporting a net loss per share. Investors and stakeholders were directed to the company’s website for further details, including the press release and slide presentation.
Wire timeline
Exagen Inc. Reports Q1 2026 Earnings Beat with $17.31M Revenue
Exagen Inc. (XGN) held its First Quarter 2026 earnings conference call on May 11, 2026, to discuss financial results for the period ended March 31, 2026. The company reported a revenue of $17.31 million, representing an 11.67% year-over-year increase and beating analyst estimates by $897,430. Additionally, Exagen posted an earnings per share (EPS) of -$0.20, which surpassed expectations by $0.05. Key executives, including CEO John Aballi and CFO Jeffrey Black, participated in the call alongside Vice President of Investor Relations Tina Jacobsen. They addressed questions from analysts representing major financial institutions such as Canaccord Genuity, Craig-Hallum Capital Group, TD Cowen, BTIG, and KeyBanc Capital Markets. The discussion likely covered operational performance, strategic initiatives, and future outlooks, although specific dialogue details were not provided in the transcript header. The event underscores Exagen's continued financial trajectory in the diagnostic testing sector, highlighting its ability to exceed market expectations despite reporting a net loss per share. Investors and stakeholders were directed to the company’s website for further details, including the press release and slide presentation.
All Articles on Seeking Alpha